AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 FEB 12 - (NewsRx.com & NewsRx.net) -- A recombinant vaccine comprised of the hepatitis C virus (HCV) NS3 protein and an adenoviral vector has induced immune response in animal models.
According to a study from Spain, "cellular immune response plays an important role in the clearance of hepatitis C virus (HCV). Thus, development of efficient ways to induce anti-viral cellular immune responses is an important step toward prevention and/or treatment of HCV infection. With this aim, we have constructed a replication-deficient recombinant adenovirus expressing HCV NS3 protein (RAdNS3)."
"The efficacy of RAdNS3 was tested in vivo by measuring the protection against infection with a recombinant vaccinia virus expressing HCV-polyprotein (vHCV1-3011). Immunization with 10(9) pfu of RAdNS3 induced anti-NS3 humoral, T helper and T cytotoxic responses," stated L. Arribillaga and coauthors, University of Navarra, CIMA.
"We identified eight epitopes recognized by IFN-gamma producing cells, five of them exhibiting lytic activity. Moreover, we show that RAdNS3 immunized mice were protected against challenge with vHCV1-3011 and that this protection was mediated by ...